Henshaw Capital’s AtriCure ATRC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-15,560
Closed -$548K 171
2025
Q3
$548K Sell
15,560
-3,542
-19% -$122K 0.02% 168
2025
Q2
$626K Hold
19,102
0.02% 206
2025
Q1
$616K Hold
19,102
0.03% 200
2024
Q4
$584K Hold
19,102
0.02% 190
2024
Q3
$536K Buy
19,102
+6,061
+46% +$149K 0.02% 209
2024
Q2
$297K Buy
13,041
+2,224
+21% +$51.3K 0.01% 248
2024
Q1
$329K Hold
10,817
0.02% 230
2023
Q4
$386K Hold
10,817
0.02% 204
2023
Q3
$474K Buy
10,817
+4,732
+78% +$231K 0.03% 162
2023
Q2
$300K Hold
6,085
0.02% 182
2023
Q1
$252K Hold
6,085
0.02% 200
2022
Q4
$270K Hold
6,085
0.02% 191
2022
Q3
$238K Hold
6,085
0.02% 245
2022
Q2
$249K Buy
6,085
+1,218
+25% +$57.7K 0.02% 254
2022
Q1
$320K Hold
4,867
0.02% 235
2021
Q4
$338K Hold
4,867
0.02% 235
2021
Q3
$339K Buy
4,867
+458
+10% +$35.2K 0.02% 230
2021
Q2
$350K Buy
4,409
+1,094
+33% +$79.5K 0.02% 248
2021
Q1
$217K Buy
+3,315
New +$204K 0.01% 323

Other funds holding ATRC

Henshaw Capital's ATRC Position: Q4 2025 in Review

Henshaw Capital sold out of AtriCure (ATRC) in Q4 2025, closing a stake of 15,560 shares — an estimated $548K sold.

Henshaw Capital first reported a position in ATRC in Q1 2021 and held it in 19 quarters. The position peaked at $626K in Q2 2025. 233 funds tracked by Wall St. Rank hold ATRC as of Q4 2025.

  • Henshaw Capital reported no remaining AtriCure position as of Q4 2025 after selling out during the quarter.
  • Henshaw Capital sold 15,560 AtriCure shares in Q4 2025, an estimated $548K.
  • Henshaw Capital first reported a position in AtriCure in Q1 2021 and held it in 19 quarters.
  • Henshaw Capital's AtriCure position peaked at $626K in Q2 2025.
  • 233 funds tracked by Wall St. Rank held AtriCure as of Q4 2025.

Based on Henshaw Capital's 13F filing for Q4 2025, filed 28 May 2026.